Literature DB >> 1970459

Seroepidemiology of human T cell lymphotropic virus in the Republic of Panama.

W C Reeves1, P H Levine, M Cuevas, E Quiroz, E Maloney, W C Saxinger.   

Abstract

The human T-lymphotropic virus (HTLV) and associated diseases, adult T cell leukemia and spastic paraparesis, appear to be endemic in southwestern Japan and the Caribbean. This cross-sectional population-based study was conducted to describe the seroepidemiology of HTLV in the Republic of Panama. HTLV antibody was measured by first generation and commercial ELISA tests and confirmed by competitive binding ELISA, a radioimmunoassay for anti-p 24, and Western blot. Of 3,231 subjects greater than or equal to 15 years of age, 135 (4.2%) had antibody detected in ELISA screening tests, but because only 20% were confirmed positive, HTLV seroprevalence varied from 0.2-2% throughout the Republic. Infection with HTLV clustered in Guaymi Indians living in Bocas del Toro province (9.9% prevalence rate). With the exception of Guaymi Indians, no major geographic, urban/rural, male/female or racial differences in antibody prevalence were observed; specifically, HTLV infection rates were not elevated in black Panamanians. Clustering of infection in an isolated Amerind population must be further investigated. The small proportion of screen-positive sera which confirmed positive illustrates the importance of strict uniform criteria for seropositivity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1970459     DOI: 10.4269/ajtmh.1990.42.374

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  9 in total

Review 1.  The origin and evolution of human T-cell lymphotropic virus types I and II.

Authors:  Y Suzuki; T Gojobori
Journal:  Virus Genes       Date:  1998       Impact factor: 2.332

2.  Complete nucleotide sequence of an Amerindian human T-cell lymphotropic virus type II (HTLV-II) isolate: identification of a variant HTLV-II subtype b from a Guaymi Indian.

Authors:  D Pardi; W M Switzer; K G Hadlock; J E Kaplan; R B Lal; T M Folks
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

3.  Isolation of human T-cell lymphotropic virus type 2 from Guaymi Indians in Panama.

Authors:  M D Lairmore; S Jacobson; F Gracia; B K De; L Castillo; M Larreategui; B D Roberts; P H Levine; W A Blattner; J E Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

Review 4.  Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection.

Authors:  Nicolas Legrand; Skye McGregor; Rowena Bull; Sahar Bajis; Braulio Mark Valencia; Amrita Ronnachit; Lloyd Einsiedel; Antoine Gessain; John Kaldor; Marianne Martinello
Journal:  Clin Microbiol Rev       Date:  2022-02-23       Impact factor: 50.129

5.  Post-transplantation HTLV-1 myelopathy in three recipients from a single donor.

Authors:  J J Zarranz Imirizaldu; J C Gomez Esteban; I Rouco Axpe; T Perez Concha; F Velasco Juanes; I Allue Susaeta; J M Corral Carranceja
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-08       Impact factor: 10.154

6.  Isolation and characterization of simian T-cell leukemia virus type II from New World monkeys.

Authors:  Y M Chen; Y J Jang; P J Kanki; Q C Yu; J J Wang; R J Montali; K P Samuel; T S Papas
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

7.  Virologic and genetic studies relate Amerind origins to the indigenous people of the Mongolia/Manchuria/southeastern Siberia region.

Authors:  J V Neel; R J Biggar; R I Sukernik
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-25       Impact factor: 11.205

8.  Multiple isolates and characteristics of human T-cell leukemia virus type II.

Authors:  W W Hall; H Takahashi; C Liu; M H Kaplan; O Scheewind; S Ijichi; K Nagashima; R C Gallo
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

9.  Epidemiological Aspects and World Distribution of HTLV-1 Infection.

Authors:  Antoine Gessain; Olivier Cassar
Journal:  Front Microbiol       Date:  2012-11-15       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.